Compare ALKS & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALKS | LAZ |
|---|---|---|
| Founded | 1987 | 1848 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.7B |
| IPO Year | 1991 | 2005 |
| Metric | ALKS | LAZ |
|---|---|---|
| Price | $28.07 | $48.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 9 |
| Target Price | $42.85 | ★ $55.38 |
| AVG Volume (30 Days) | ★ 1.6M | 954.8K |
| Earning Date | 02-11-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 4.05% |
| EPS Growth | ★ 2.44 | N/A |
| EPS | 2.02 | ★ 2.52 |
| Revenue | $1,521,338,000.00 | ★ $3,016,853,000.00 |
| Revenue This Year | N/A | $0.62 |
| Revenue Next Year | $24.22 | $17.34 |
| P/E Ratio | ★ $13.82 | $19.64 |
| Revenue Growth | ★ 1.08 | N/A |
| 52 Week Low | $25.17 | $31.97 |
| 52 Week High | $36.45 | $58.07 |
| Indicator | ALKS | LAZ |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 40.61 |
| Support Level | $27.66 | $48.83 |
| Resistance Level | $28.67 | $50.29 |
| Average True Range (ATR) | 0.67 | 1.23 |
| MACD | 0.01 | -0.23 |
| Stochastic Oscillator | 24.73 | 0.00 |
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.